Your browser doesn't support javascript.
loading
Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness?
Roccuzzo, Gabriele; Rozzo, Giulia; Burzi, Lorenza; Repetto, Federica; Dapavo, Paolo; Ribero, Simone; Quaglino, Pietro.
Afiliação
  • Roccuzzo G; Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy.
  • Rozzo G; Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy.
  • Burzi L; Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy.
  • Repetto F; Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy.
  • Dapavo P; Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy.
  • Ribero S; Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy.
  • Quaglino P; Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy.
Dermatol Ther ; 35(11): e15803, 2022 11.
Article em En | MEDLINE | ID: mdl-36062429
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hidradenite Supurativa / Medicamentos Biossimilares Tipo de estudo: Diagnostic_studies / Health_economic_evaluation / Observational_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hidradenite Supurativa / Medicamentos Biossimilares Tipo de estudo: Diagnostic_studies / Health_economic_evaluation / Observational_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article